Transcatheter aortic valve replacement for the treatment of severe aortic valve stenosis_West China Medical Journal

Authors：

HUANG Qianhai ¹ , LIU Qianjin ² , ZHANG Huakun ¹ , MA Lu ¹ , WANG Sheng ² ,  CHENG Zhaoyun ^1,2

1. Department of Cardiovascular Surgery, People’s Hospital of Henan University / Henan Provincial People’s Hospital, Zhengzhou, Henan 450003, P. R. China;
2. Department of Cardiovascular Surgery, Heart Center of Henan Provincial People’s Hospital / Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan 451464, P. R. China;

Corresponding author：

CHENG Zhaoyun, Email: 13903712068@163.com

Keywords：

Aortic stenosis; Transcatheter aortic valve replacement; Surgical aortic valve replacement; Complications

DOI：

10.7507/1002-0179.201912083

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Transcatheter aortic valve replacement (TAVR) is a minimally invasive approach to treat symptomatic severe aortic stenosis with surgical taboos or high risk. With the update of the guidelines, the indication of TAVR has been extended to the intermediate-risk aortic stenosis population, and even has a tendency to further expand to the low-risk population. This review highlights the research progress and new evidence of TAVR in respects of patient selection, valve and approach selection, ethnic differences, and surgical complications such as perivalvular leakage, cardiac conduction block, vascular complications, stroke, acute kidney injury, and coronary artery occlusion.

Citation： HUANG Qianhai, LIU Qianjin, ZHANG Huakun, MA Lu, WANG Sheng, CHENG Zhaoyun. Transcatheter aortic valve replacement for the treatment of severe aortic valve stenosis. West China Medical Journal, 2020, 35(4): 494-502. doi: 10.7507/1002-0179.201912083 Copy

1.	Arora S, Misenheimer JA, Ramaraj R. Transcatheter aortic valve replacement: comprehensive review and present status. Texas Heart Inst J, 2017, 44(1): 29-38.
2.	高润霖. 中国心瓣膜病现状. 华西医学, 2018, 33(2): 127-131.
3.	Jeremy JT, Vuyisile TN, Rakesh MS, et al. Sex-related differences in calcific aortic stenosis: correlating clinical and echocardiographic characteristics and computed tomography aortic valve calcium score to excised aortic valve weight. Eur Heart J, 2016, 37(8): 693-699.
4.	Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation, 2002, 106(24): 3006-3008.
5.	Morís C, Pascual I, Avanzas P. Will TAVI be the standard of care in the treatment of aortic stenosis?. Rev Esp Cardiol (Engl Ed), 2016, 69(12): 1131-1134.
6.	潘文志, 周达新, 葛均波. 经导管主动脉瓣置换术的中国现状 2017. 华西医学, 2018, 33(2): 132-136.
7.	Bavaria JE, Tommaso CL, Brindis RG, et al. 2018 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Aortic Valve Replacement: a joint report of the American Association for Thoracic Surgery, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2019, 73(3): 340-374.
8.	Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129(23): 2440-2492.
9.	Kang DH, Park SJ, Sa LE, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med, 2020, 382(2): 111-119.
10.	Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2016, 374(17): 1609-1620.
11.	Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
12.	Reardon MJ, van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2017, 376(14): 1321-1331.
13.	Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
14.	Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg, 2012, 42(4): S1-44.
15.	Burgazlı KM, Chasan R, Kavukçu E, et al. Transcatheter aortic valve implantation: our experience and review of the literature. Balkan Med J, 2012, 29(2): 118-123.
16.	Baumgartner H. The 2017 ESC/EACTS guidelines on the management of valvular heart disease. Wien Klin Wochenschr, 2018, 130(5/6): 168-171.
17.	Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2017, 135(25): E1159.
18.	Parma R, Hudziak D, Smolka G, et al. SAPIEN 3 ultra: design and procedural features of a new balloon-expandable valve. Cardiol J, 2019.
19.	Saia F, Gandolfo C, Palmerini T, et al. In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry. EuroIntervention, 2020, 15(14): 1240-1247.
20.	Solomonica A, Choudhury T, Rodrigo B. Newer-generation of edwards transcatheter aortic valve systems: SAPIEN 3, centera, and SAPIEN 3 ultra. Expert Rev Med Devices, 2019, 16(2): 81-87.
21.	Choudhury T, Solomonica A, Rodrigo B. The evolut R and evolut PRO transcatheter aortic valve systems. Expert Rev Med Devices, 2019, 16(1): 3-9.
22.	Mahtta D, Elgendy IY, Anthony AB. From CoreValve to evolut PRO: reviewing the journey of self-expanding transcatheter aortic valves. Cardiol Ther, 2017, 6(2): 183-192.
23.	Forrest JK, Mangi AA, Popma JJ, et al. Early outcomes with the evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv, 2018, 11(2): 160-168.
24.	连淑芬. J-Valve^TM 行经心尖经导管主动脉瓣置换术治疗高危单纯无钙化主动脉瓣关闭不全研究. 中国医疗器械信息, 2019, 25(12): 63-64, 136.
25.	Zhou DX, Pan WZ, Wang JA, et al. VitaFlow^TM transcatheter valve system in the treatment of severe aortic stenosis: one-year results of a multicenter study. Catheter Cardiovasc Interv, 2020, 95(2): 332-338.
26.	Pour-Ghaz I, Raja J, Bayoumi M, et al. Transcatheter aortic valve replacement with a focus on transcarotid: a review of the current literature. Ann Transl Med, 2019, 7(17): 420-420.
27.	Yong Z, Saadat S, Soin A, et al. A meta-analysis comparing transaxillary and transfemoral transcatheter aortic valve replacement. J Thorac Dis, 2019, 11(12): 5140-5151.
28.	Batchelor W, Patel K, Hurt J, et al. Incidence, prognosis and predictors of major vascular complications and percutaneous closure device failure following contemporary percutaneous transfemoral transcatheter aortic valve replacement. Cardiovasc Revasc Med, 2020.
29.	Overtchouk P, Modine T. Alternate access for TAVI: stay clear of the chest. Interv Cardiol, 2018, 13(3): 145-150.
30.	Elmariah S, Fearon WF, Inglessis I, et al. Transapical transcatheter aortic valve replacement is associated with increased cardiac mortality in patients with left ventricular dysfunction: insights from the PARTNER I trial. JACC Cardiovasc Interv, 2017, 10(23): 2414-2422.
31.	Allen KB, Chhatriwalla AK, Cohen D, et al. Transcarotid versus transapical and transaortic access for transcatheter aortic valve replacement. Ann Thorac Surg, 2019, 108(3): 715-722.
32.	Chollet T, Marcheix B, Boudou N, et al. Propensity-matched comparison of clinical outcomes after transaortic versus transfemoral aortic valve replacement. EuroIntervention, 2018, 14(7): 750-757.
33.	Gleason TG, Schindler JT, Hagberg RC, et al. Subclavian/axillary access for self-expanding transcatheter aortic valve replacement renders equivalent outcomes as transfemoral. Ann Thorac Surg, 2018, 105(2): 477-483.
34.	Dahle TG, Kaneko T, Mccabe JM. Outcomes following subclavian and axillary artery access for transcatheter aortic valve replacement: society of the thoracic surgeons/American College of Cardiology TVT Registry Report. JACC Cardiovasc Interv, 2019, 12(7): 662-669.
35.	Bapat V, Tang GHL. Axillary/subclavian transcatheter aortic valve replacement: the default alternative access?. JACC Cardiovasc Interv, 2019, 12(7): 670-672.
36.	Bob-Manuel T, Almusawi H, Rezan T, et al. Efficacy and safety of transcarotid transcatheter aortic valve replacement: a systematic review. Cardiovasc Revasc Med, 2019.
37.	Young MN, Singh V, Sakhuja R. A review of alternative access for transcatheter aortic valve replacement. Curr Treat Options Cardiovasc Med, 2018, 20(7): 62.
38.	Campelo-Parada F, Rodés-Cabau J, Dumont E, et al. A novel transcarotid approach for implantation of balloon-expandable or self-expandable transcatheter aortic valves. Can J Cardiol, 2016, 32(12): 1575.e9-1575.e12.
39.	Overtchouk P, Folliguet T, Pinaud F, et al. Transcarotid approach for transcatheter aortic valve replacement with the Sapien 3 prosthesis: a multicenter French registry. JACC Cardiovasc Interv, 2019, 12(5): 413-419.
40.	Paone G, Eng M, Kabbani LS, et al. Transcatheter aortic valve replacement: comparing transfemoral, transcarotid, and transcaval access. Ann Thorac Surg, 2018, 106(4): 1105-1112.
41.	Watanabe M, Takahashi S, Yamaoka H, et al. Comparison of transcarotid vs. transfemoral transcatheter aortic valve implantation. Circ J, 2018, 82(10): 2518-2522.
42.	Kirker EB, Hodson RW, Spinelli KJ, et al. The carotid artery as a preferred alternative access route for transcatheter aortic valve replacement. Ann Thorac Surg, 2017, 104(2): 621-629.
43.	Chamandi C, Abi-Akar R, Rodés-Cabau J, et al. Transcarotid compared with other alternative access routes for transcatheter aortic valve replacement. Circ Cardiovasc Interv, 2018, 11(11): e006388.
44.	Watanabe Y, Hayashida K, Thierry L, et al. Transcatheter aortic valve implantation in patients of small body size. Catheter Cardiovasc Interv, 2014, 84(2): 272-280.
45.	Chiam PT, Koh AS, Ewe SH, et al. Iliofemoral anatomy among Asians: implications for transcatheter aortic valve implantation. Int J Cardiol, 2013, 167(4): 1373-1379.
46.	Watanabe Y, Hayashida K, Takayama M, et al. First direct comparison of clinical outcomes between European and Asian cohorts in transcatheter aortic valve implantation: the Massy study group vs. the PREVAIL Japan trial. J Cardiol, 2015, 65(2): 112-116.
47.	Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the evolut R U.S. study. JACC Cardiovasc Interv, 2017, 10(3): 268-275.
48.	Chew N, Hon JK, Yip WL, et al. Mid-term study of transcatheter aortic valve implantation in an Asian population with severe aortic stenosis: two-year Valve Academic Research Consortium-2 outcomes. Singapore Med J, 2017, 58(9): 543-550.
49.	Jilaihawi H, Wu YJ, Yang YE, et al. Morphological characteristics of severe aortic stenosis in China: imaging corelab observations from the first Chinese transcatheter aortic valve trial. Catheter Cardiovasc Interv, 2015, 85(1): 752-761.
50.	Ram D, Ismail B, Karliova I, et al. Concepts of bicuspid aortic valve repair: a review. Ann Thorac Surg, 2020, 109(4): 999-1006.
51.	Costopoulos C, Latib A, Maisano F, et al. Comparison of results of transcatheter aortic valve implantation in patients with severely stenotic bicuspid versus tricuspid or nonbicuspid valves. Am J Cardiol, 2014, 113(8): 1390-1393.
52.	Kochman J, Huczek Z, Scisło P, et al. Comparison of one- and 12-month outcomes of transcatheter aortic valve replacement in patients with severely stenotic bicuspid versus tricuspid aortic valves (results from a multicenter registry). Am J Cardiol, 2014, 114(5): 757-762.
53.	Jilaihawi H, Chen M, Webb J, et al. A bicuspid aortic valve imaging classification for the TAVR era. JACC Cardiovasc Imaging, 2016, 9(10): 1145-1158.
54.	Zhao ZG, Jilaihawi H, Feng Y, et al. Transcatheter aortic valve implantation in bicuspid anatomy. Nat Rev Cardiol, 2015, 12(2): 123-128.
55.	Li YJ, Wei X, Zhao ZA, et al. Prevalence and complications of bicuspid aortic valve in Chinese according to echocardiographic database. Am J Cardiol, 2017, 120(2): 287-291.
56.	Ueshima D, Nai Fovino L, Brener SJ, et al. Transcatheter aortic valve replacement for bicuspid aortic valve stenosis with first- and new-generation bioprostheses: a systematic review and meta-analysis. Int J Cardiol, 2020, 298: 76-82.
57.	Montone RA, Luca T, Chiara F, et al. Procedural and 30-day clinical outcomes following transcatheter aortic valve replacement with lotus valve: results of the RELEVANT study. Catheter Cardiovasc Interv, 2017, 90(7): 1206-1211.
58.	Presbitero P, Iannetta L, Pagnotta P, et al. Transcatheter aortic valve implantation in bicuspid anatomy: procedural results with two different types of valves. Minerva Cardioangiol, 2018, 66(2): 129-135.
59.	Rashid HNZ, Gooley R, McCormick L, et al. Safety and efficacy of valve repositioning during transcatheter aortic valve replacement with the Lotus Valve System. J Cardiol, 2017, 70(1): 55-61.
60.	Xu Q, Liu X, Jiang J, et al. Transcatheter aortic valve replacement in atypical valve anatomy using the Lotus valve: a Chinese single-center experience. Herz, 2019.
61.	Cormican D, Jayaraman A, Villablanca P, et al. TAVR procedural volumes and patient outcomes: analysis of recent data. J Cardiothorac Vasc Anesth, 2020, 34(2): 545-550.
62.	Sud M, Tam DY, Wijeysundera HC. The economics of transcatheter valve interventions. Can J Cardiol, 2017, 33(9): 1091-1098.
63.	Takagi H, Umemoto T. Impact of paravalvular aortic regurgitation after transcatheter aortic valve implantation on survival. Int J Cardiol, 2016, 221: 46-51.
64.	Haensig M, Lehmkuhl L, Linke A, et al. Aortic valve Calcium score for paravalvular aortic insufficiency (AVCS II) study in transapical aortic valve implantation. Heart Surg Forum, 2016, 19(1): E36-E42.
65.	Waterbury TM, Reeder GS, Pislaru SV, et al. Techniques and outcomes of paravalvular leak repair after transcatheter aortic valve replacement. Catheter Cardiovasc Interv, 2017, 90(5): 870-877.
66.	van Mieghem NM, Wöhrle J, Hildick-Smith D, et al. Use of a repositionable and fully retrievable aortic valve in routine clinical practice: the RESPOND study and RESPOND extension cohort. JACC Cardiovasc Interv, 2019, 12(1): 38-49.
67.	Rao G, Sheth S, Donnelly J, et al. Early real-world experience with CoreValve Evolut PRO and R systems for transcatheter aortic valve replacement. J Interv Cardiol, 2019, 2019: 1906814.
68.	Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med, 2010, 363(17): 1597-1607.
69.	Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv, 2015, 8(1 Pt A): 60-69.
70.	Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation, 2017, 136(11): 1049-1069.
71.	Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med, 2011, 364(23): 2187-2198.
72.	ElGuindy A. PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients. Glob Cardiol Sci Pract, 2017, 2016(4): e201633.
73.	Kodali S, Thourani VH, White JA, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J, 2016, 37(28): 2252-2262.
74.	Falk V, Jochen W, Hildick-Smith D, et al. Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study. Eur Heart J, 2017, 38(45): 3359-3366.
75.	Reardon MJ, Feldman TE, Meduri CU, et al. Two-Year outcomes after transcatheter aortic valve replacement with mechanical vs self-expanding valves: the REPRISE III randomized clinical trial. JAMA Cardiol, 2019, 4(3): 223-229.
76.	Sherwood MW, Xiang K, Matsouaka R, et al. Incidence, temporal trends, and associated outcomes of vascular and bleeding complications in patients undergoing transfemoral transcatheter aortic valve replacement: insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. Circ Cardiovasc Interv, 2020, 13(1): e008227.
77.	Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv, 2014, 7(8): 898-904.
78.	Carroll JD, Vemulapalli S, Dai D, et al. Procedural experience for transcatheter aortic valve replacement and relation to outcomes: the STS/ACC TVT registry. J Am Coll Cardiol, 2017, 70(1): 29-41.
79.	Généreux P, Webb JG, Svensson LG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol, 2012, 60(12): 1043-1052.
80.	Van Mieghem NM, Nuis RJ, Piazza N, et al. Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System®: the Rotterdam experience. EuroIntervention, 2010, 5(6): 673-679.
81.	Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral artery disease and transcatheter aortic valve replacement outcomes: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry. Circ Cardiovasc Interv, 2017, 10(10): e005456.
82.	van Kesteren F, van Mourik MS, Vendrik J, et al. Incidence, predictors, and impact of vascular complications after transfemoral transcatheter aortic valve implantation with the SAPIEN 3 prosthesis. Am J Cardiol, 2018, 121(10): 1231-1238.
83.	Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med, 2014, 370(19): 1790-1798.
84.	Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation, 2012, 126(25): 3041-3053.
85.	Bagur R, Solo K, Alghofaili S, et al. Cerebral embolic protection devices during transcatheter aortic valve implantation: systematic review and meta-analysis. Stroke, 2017, 48(5): 1306-1315.
86.	Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol, 2017, 69(4): 367-377.
87.	Gasior T, Mangner N, Bijoch J, et al. Cerebral embolic protection systems for transcatheter aortic valve replacement. J Interv Cardiol, 2018, 31(6): 891-898.
88.	Langfritz M, Shahin M, Nietlispach F, et al. Baseline predictors of renal failure in transcatheter aortic valve implantation. J Invasive Cardiol, 2019, 31(10): E289-E297.
89.	Terré JA, George I, Smith CR. Pros and cons of transcatheter aortic valve implantation (TAVI). Ann Cardiothorac Surg, 2017, 6(5): 444-452.
90.	Miura D, Yamada Y, Kusaba S, et al. Influence of preoperative serum creatinine level and intraoperative volume of contrast medium on the risk of acute kidney injury after transfemoral transcatheter aortic valve implantation: a retrospective observational study. BMC Res Notes, 2019, 12(1): 484.
91.	Attard S, Buttigieg J, Galea S, et al. The incidence, predictors, and prognosis of acute kidney injury after transcatheter aortic valve implantation. Clin Nephrol, 2018, 90(6): 373-379.
92.	Chatani K, Abdel-Wahab M, Wübken-Kleinfeld N, et al. Acute kidney injury after transcatheter aortic valve implantation: impact of contrast agents, predictive factors, and prognostic importance in 203 patients with long-term follow-up. J Cardiol, 2015, 66(6): 514-519.
93.	Elhmidi Y, Bleiziffer S, Marcus-André D, et al. Acute kidney injury after transcatheter aortic valve implantation: incidence, predictors and impact on mortality. Arch Cardiovasc Dis, 2014, 107(2): 133-139.
94.	Arbel Y, Ben-Assa E, Puzhevsky D, et al. Forced diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI). Eur Heart J, 2019, 40(38): 3169-3178.
95.	Scarsini R, De Maria GL, Joseph J, et al. Impact of complications during transfemoral transcatheter aortic valve replacement: how can they be avoided and managed?. J Am Heart Assoc, 2019, 8(18): e013801.
96.	Dvir D, Leipsic J, Blanke P, et al. Coronary obstruction in transcatheter aortic valve-in-valve implantation: preprocedural evaluation, device selection, protection, and treatment. Circ Cardiovasc Interv, 2015, 8(1): e002079.
97.	Vollema EM, Delgado V, Bax JJ. Echocardiography in transcatheter aortic valve replacement. Heart Lung Circ, 2019, 28(9): 1384-1399.
98.	Khan JM, Greenbaum AB, Babaliaros VC, et al. The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv, 2019, 12(13): 1240-1252.

1. Arora S, Misenheimer JA, Ramaraj R. Transcatheter aortic valve replacement: comprehensive review and present status. Texas Heart Inst J, 2017, 44(1): 29-38.
2. 高润霖. 中国心瓣膜病现状. 华西医学, 2018, 33(2): 127-131.
3. Jeremy JT, Vuyisile TN, Rakesh MS, et al. Sex-related differences in calcific aortic stenosis: correlating clinical and echocardiographic characteristics and computed tomography aortic valve calcium score to excised aortic valve weight. Eur Heart J, 2016, 37(8): 693-699.
4. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation, 2002, 106(24): 3006-3008.
5. Morís C, Pascual I, Avanzas P. Will TAVI be the standard of care in the treatment of aortic stenosis?. Rev Esp Cardiol (Engl Ed), 2016, 69(12): 1131-1134.
6. 潘文志, 周达新, 葛均波. 经导管主动脉瓣置换术的中国现状 2017. 华西医学, 2018, 33(2): 132-136.
7. Bavaria JE, Tommaso CL, Brindis RG, et al. 2018 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Aortic Valve Replacement: a joint report of the American Association for Thoracic Surgery, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2019, 73(3): 340-374.
8. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129(23): 2440-2492.
9. Kang DH, Park SJ, Sa LE, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med, 2020, 382(2): 111-119.
10. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2016, 374(17): 1609-1620.
11. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
12. Reardon MJ, van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2017, 376(14): 1321-1331.
13. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
14. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg, 2012, 42(4): S1-44.
15. Burgazlı KM, Chasan R, Kavukçu E, et al. Transcatheter aortic valve implantation: our experience and review of the literature. Balkan Med J, 2012, 29(2): 118-123.
16. Baumgartner H. The 2017 ESC/EACTS guidelines on the management of valvular heart disease. Wien Klin Wochenschr, 2018, 130(5/6): 168-171.
17. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2017, 135(25): E1159.
18. Parma R, Hudziak D, Smolka G, et al. SAPIEN 3 ultra: design and procedural features of a new balloon-expandable valve. Cardiol J, 2019.
19. Saia F, Gandolfo C, Palmerini T, et al. In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry. EuroIntervention, 2020, 15(14): 1240-1247.
20. Solomonica A, Choudhury T, Rodrigo B. Newer-generation of edwards transcatheter aortic valve systems: SAPIEN 3, centera, and SAPIEN 3 ultra. Expert Rev Med Devices, 2019, 16(2): 81-87.
21. Choudhury T, Solomonica A, Rodrigo B. The evolut R and evolut PRO transcatheter aortic valve systems. Expert Rev Med Devices, 2019, 16(1): 3-9.
22. Mahtta D, Elgendy IY, Anthony AB. From CoreValve to evolut PRO: reviewing the journey of self-expanding transcatheter aortic valves. Cardiol Ther, 2017, 6(2): 183-192.
23. Forrest JK, Mangi AA, Popma JJ, et al. Early outcomes with the evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv, 2018, 11(2): 160-168.
24. 连淑芬. J-Valve^TM 行经心尖经导管主动脉瓣置换术治疗高危单纯无钙化主动脉瓣关闭不全研究. 中国医疗器械信息, 2019, 25(12): 63-64, 136.
25. Zhou DX, Pan WZ, Wang JA, et al. VitaFlow^TM transcatheter valve system in the treatment of severe aortic stenosis: one-year results of a multicenter study. Catheter Cardiovasc Interv, 2020, 95(2): 332-338.
26. Pour-Ghaz I, Raja J, Bayoumi M, et al. Transcatheter aortic valve replacement with a focus on transcarotid: a review of the current literature. Ann Transl Med, 2019, 7(17): 420-420.
27. Yong Z, Saadat S, Soin A, et al. A meta-analysis comparing transaxillary and transfemoral transcatheter aortic valve replacement. J Thorac Dis, 2019, 11(12): 5140-5151.
28. Batchelor W, Patel K, Hurt J, et al. Incidence, prognosis and predictors of major vascular complications and percutaneous closure device failure following contemporary percutaneous transfemoral transcatheter aortic valve replacement. Cardiovasc Revasc Med, 2020.
29. Overtchouk P, Modine T. Alternate access for TAVI: stay clear of the chest. Interv Cardiol, 2018, 13(3): 145-150.
30. Elmariah S, Fearon WF, Inglessis I, et al. Transapical transcatheter aortic valve replacement is associated with increased cardiac mortality in patients with left ventricular dysfunction: insights from the PARTNER I trial. JACC Cardiovasc Interv, 2017, 10(23): 2414-2422.
31. Allen KB, Chhatriwalla AK, Cohen D, et al. Transcarotid versus transapical and transaortic access for transcatheter aortic valve replacement. Ann Thorac Surg, 2019, 108(3): 715-722.
32. Chollet T, Marcheix B, Boudou N, et al. Propensity-matched comparison of clinical outcomes after transaortic versus transfemoral aortic valve replacement. EuroIntervention, 2018, 14(7): 750-757.
33. Gleason TG, Schindler JT, Hagberg RC, et al. Subclavian/axillary access for self-expanding transcatheter aortic valve replacement renders equivalent outcomes as transfemoral. Ann Thorac Surg, 2018, 105(2): 477-483.
34. Dahle TG, Kaneko T, Mccabe JM. Outcomes following subclavian and axillary artery access for transcatheter aortic valve replacement: society of the thoracic surgeons/American College of Cardiology TVT Registry Report. JACC Cardiovasc Interv, 2019, 12(7): 662-669.
35. Bapat V, Tang GHL. Axillary/subclavian transcatheter aortic valve replacement: the default alternative access?. JACC Cardiovasc Interv, 2019, 12(7): 670-672.
36. Bob-Manuel T, Almusawi H, Rezan T, et al. Efficacy and safety of transcarotid transcatheter aortic valve replacement: a systematic review. Cardiovasc Revasc Med, 2019.
37. Young MN, Singh V, Sakhuja R. A review of alternative access for transcatheter aortic valve replacement. Curr Treat Options Cardiovasc Med, 2018, 20(7): 62.
38. Campelo-Parada F, Rodés-Cabau J, Dumont E, et al. A novel transcarotid approach for implantation of balloon-expandable or self-expandable transcatheter aortic valves. Can J Cardiol, 2016, 32(12): 1575.e9-1575.e12.
39. Overtchouk P, Folliguet T, Pinaud F, et al. Transcarotid approach for transcatheter aortic valve replacement with the Sapien 3 prosthesis: a multicenter French registry. JACC Cardiovasc Interv, 2019, 12(5): 413-419.
40. Paone G, Eng M, Kabbani LS, et al. Transcatheter aortic valve replacement: comparing transfemoral, transcarotid, and transcaval access. Ann Thorac Surg, 2018, 106(4): 1105-1112.
41. Watanabe M, Takahashi S, Yamaoka H, et al. Comparison of transcarotid vs. transfemoral transcatheter aortic valve implantation. Circ J, 2018, 82(10): 2518-2522.
42. Kirker EB, Hodson RW, Spinelli KJ, et al. The carotid artery as a preferred alternative access route for transcatheter aortic valve replacement. Ann Thorac Surg, 2017, 104(2): 621-629.
43. Chamandi C, Abi-Akar R, Rodés-Cabau J, et al. Transcarotid compared with other alternative access routes for transcatheter aortic valve replacement. Circ Cardiovasc Interv, 2018, 11(11): e006388.
44. Watanabe Y, Hayashida K, Thierry L, et al. Transcatheter aortic valve implantation in patients of small body size. Catheter Cardiovasc Interv, 2014, 84(2): 272-280.
45. Chiam PT, Koh AS, Ewe SH, et al. Iliofemoral anatomy among Asians: implications for transcatheter aortic valve implantation. Int J Cardiol, 2013, 167(4): 1373-1379.
46. Watanabe Y, Hayashida K, Takayama M, et al. First direct comparison of clinical outcomes between European and Asian cohorts in transcatheter aortic valve implantation: the Massy study group vs. the PREVAIL Japan trial. J Cardiol, 2015, 65(2): 112-116.
47. Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the evolut R U.S. study. JACC Cardiovasc Interv, 2017, 10(3): 268-275.
48. Chew N, Hon JK, Yip WL, et al. Mid-term study of transcatheter aortic valve implantation in an Asian population with severe aortic stenosis: two-year Valve Academic Research Consortium-2 outcomes. Singapore Med J, 2017, 58(9): 543-550.
49. Jilaihawi H, Wu YJ, Yang YE, et al. Morphological characteristics of severe aortic stenosis in China: imaging corelab observations from the first Chinese transcatheter aortic valve trial. Catheter Cardiovasc Interv, 2015, 85(1): 752-761.
50. Ram D, Ismail B, Karliova I, et al. Concepts of bicuspid aortic valve repair: a review. Ann Thorac Surg, 2020, 109(4): 999-1006.
51. Costopoulos C, Latib A, Maisano F, et al. Comparison of results of transcatheter aortic valve implantation in patients with severely stenotic bicuspid versus tricuspid or nonbicuspid valves. Am J Cardiol, 2014, 113(8): 1390-1393.
52. Kochman J, Huczek Z, Scisło P, et al. Comparison of one- and 12-month outcomes of transcatheter aortic valve replacement in patients with severely stenotic bicuspid versus tricuspid aortic valves (results from a multicenter registry). Am J Cardiol, 2014, 114(5): 757-762.
53. Jilaihawi H, Chen M, Webb J, et al. A bicuspid aortic valve imaging classification for the TAVR era. JACC Cardiovasc Imaging, 2016, 9(10): 1145-1158.
54. Zhao ZG, Jilaihawi H, Feng Y, et al. Transcatheter aortic valve implantation in bicuspid anatomy. Nat Rev Cardiol, 2015, 12(2): 123-128.
55. Li YJ, Wei X, Zhao ZA, et al. Prevalence and complications of bicuspid aortic valve in Chinese according to echocardiographic database. Am J Cardiol, 2017, 120(2): 287-291.
56. Ueshima D, Nai Fovino L, Brener SJ, et al. Transcatheter aortic valve replacement for bicuspid aortic valve stenosis with first- and new-generation bioprostheses: a systematic review and meta-analysis. Int J Cardiol, 2020, 298: 76-82.
57. Montone RA, Luca T, Chiara F, et al. Procedural and 30-day clinical outcomes following transcatheter aortic valve replacement with lotus valve: results of the RELEVANT study. Catheter Cardiovasc Interv, 2017, 90(7): 1206-1211.
58. Presbitero P, Iannetta L, Pagnotta P, et al. Transcatheter aortic valve implantation in bicuspid anatomy: procedural results with two different types of valves. Minerva Cardioangiol, 2018, 66(2): 129-135.
59. Rashid HNZ, Gooley R, McCormick L, et al. Safety and efficacy of valve repositioning during transcatheter aortic valve replacement with the Lotus Valve System. J Cardiol, 2017, 70(1): 55-61.
60. Xu Q, Liu X, Jiang J, et al. Transcatheter aortic valve replacement in atypical valve anatomy using the Lotus valve: a Chinese single-center experience. Herz, 2019.
61. Cormican D, Jayaraman A, Villablanca P, et al. TAVR procedural volumes and patient outcomes: analysis of recent data. J Cardiothorac Vasc Anesth, 2020, 34(2): 545-550.
62. Sud M, Tam DY, Wijeysundera HC. The economics of transcatheter valve interventions. Can J Cardiol, 2017, 33(9): 1091-1098.
63. Takagi H, Umemoto T. Impact of paravalvular aortic regurgitation after transcatheter aortic valve implantation on survival. Int J Cardiol, 2016, 221: 46-51.
64. Haensig M, Lehmkuhl L, Linke A, et al. Aortic valve Calcium score for paravalvular aortic insufficiency (AVCS II) study in transapical aortic valve implantation. Heart Surg Forum, 2016, 19(1): E36-E42.
65. Waterbury TM, Reeder GS, Pislaru SV, et al. Techniques and outcomes of paravalvular leak repair after transcatheter aortic valve replacement. Catheter Cardiovasc Interv, 2017, 90(5): 870-877.
66. van Mieghem NM, Wöhrle J, Hildick-Smith D, et al. Use of a repositionable and fully retrievable aortic valve in routine clinical practice: the RESPOND study and RESPOND extension cohort. JACC Cardiovasc Interv, 2019, 12(1): 38-49.
67. Rao G, Sheth S, Donnelly J, et al. Early real-world experience with CoreValve Evolut PRO and R systems for transcatheter aortic valve replacement. J Interv Cardiol, 2019, 2019: 1906814.
68. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med, 2010, 363(17): 1597-1607.
69. Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv, 2015, 8(1 Pt A): 60-69.
70. Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation, 2017, 136(11): 1049-1069.
71. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med, 2011, 364(23): 2187-2198.
72. ElGuindy A. PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients. Glob Cardiol Sci Pract, 2017, 2016(4): e201633.
73. Kodali S, Thourani VH, White JA, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J, 2016, 37(28): 2252-2262.
74. Falk V, Jochen W, Hildick-Smith D, et al. Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study. Eur Heart J, 2017, 38(45): 3359-3366.
75. Reardon MJ, Feldman TE, Meduri CU, et al. Two-Year outcomes after transcatheter aortic valve replacement with mechanical vs self-expanding valves: the REPRISE III randomized clinical trial. JAMA Cardiol, 2019, 4(3): 223-229.
76. Sherwood MW, Xiang K, Matsouaka R, et al. Incidence, temporal trends, and associated outcomes of vascular and bleeding complications in patients undergoing transfemoral transcatheter aortic valve replacement: insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. Circ Cardiovasc Interv, 2020, 13(1): e008227.
77. Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv, 2014, 7(8): 898-904.
78. Carroll JD, Vemulapalli S, Dai D, et al. Procedural experience for transcatheter aortic valve replacement and relation to outcomes: the STS/ACC TVT registry. J Am Coll Cardiol, 2017, 70(1): 29-41.
79. Généreux P, Webb JG, Svensson LG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol, 2012, 60(12): 1043-1052.
80. Van Mieghem NM, Nuis RJ, Piazza N, et al. Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System®: the Rotterdam experience. EuroIntervention, 2010, 5(6): 673-679.
81. Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral artery disease and transcatheter aortic valve replacement outcomes: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry. Circ Cardiovasc Interv, 2017, 10(10): e005456.
82. van Kesteren F, van Mourik MS, Vendrik J, et al. Incidence, predictors, and impact of vascular complications after transfemoral transcatheter aortic valve implantation with the SAPIEN 3 prosthesis. Am J Cardiol, 2018, 121(10): 1231-1238.
83. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med, 2014, 370(19): 1790-1798.
84. Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation, 2012, 126(25): 3041-3053.
85. Bagur R, Solo K, Alghofaili S, et al. Cerebral embolic protection devices during transcatheter aortic valve implantation: systematic review and meta-analysis. Stroke, 2017, 48(5): 1306-1315.
86. Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol, 2017, 69(4): 367-377.
87. Gasior T, Mangner N, Bijoch J, et al. Cerebral embolic protection systems for transcatheter aortic valve replacement. J Interv Cardiol, 2018, 31(6): 891-898.
88. Langfritz M, Shahin M, Nietlispach F, et al. Baseline predictors of renal failure in transcatheter aortic valve implantation. J Invasive Cardiol, 2019, 31(10): E289-E297.
89. Terré JA, George I, Smith CR. Pros and cons of transcatheter aortic valve implantation (TAVI). Ann Cardiothorac Surg, 2017, 6(5): 444-452.
90. Miura D, Yamada Y, Kusaba S, et al. Influence of preoperative serum creatinine level and intraoperative volume of contrast medium on the risk of acute kidney injury after transfemoral transcatheter aortic valve implantation: a retrospective observational study. BMC Res Notes, 2019, 12(1): 484.
91. Attard S, Buttigieg J, Galea S, et al. The incidence, predictors, and prognosis of acute kidney injury after transcatheter aortic valve implantation. Clin Nephrol, 2018, 90(6): 373-379.
92. Chatani K, Abdel-Wahab M, Wübken-Kleinfeld N, et al. Acute kidney injury after transcatheter aortic valve implantation: impact of contrast agents, predictive factors, and prognostic importance in 203 patients with long-term follow-up. J Cardiol, 2015, 66(6): 514-519.
93. Elhmidi Y, Bleiziffer S, Marcus-André D, et al. Acute kidney injury after transcatheter aortic valve implantation: incidence, predictors and impact on mortality. Arch Cardiovasc Dis, 2014, 107(2): 133-139.
94. Arbel Y, Ben-Assa E, Puzhevsky D, et al. Forced diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI). Eur Heart J, 2019, 40(38): 3169-3178.
95. Scarsini R, De Maria GL, Joseph J, et al. Impact of complications during transfemoral transcatheter aortic valve replacement: how can they be avoided and managed?. J Am Heart Assoc, 2019, 8(18): e013801.
96. Dvir D, Leipsic J, Blanke P, et al. Coronary obstruction in transcatheter aortic valve-in-valve implantation: preprocedural evaluation, device selection, protection, and treatment. Circ Cardiovasc Interv, 2015, 8(1): e002079.
97. Vollema EM, Delgado V, Bax JJ. Echocardiography in transcatheter aortic valve replacement. Heart Lung Circ, 2019, 28(9): 1384-1399.
98. Khan JM, Greenbaum AB, Babaliaros VC, et al. The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv, 2019, 12(13): 1240-1252.

Previous Article
Analysis of influencing factors of muscle loss in patients undergoing maintenance hemodialysis
Next Article
鼻翼内侧鼻前庭倒置性毛囊角化病一例

West China Medical Journal

Transcatheter aortic valve replacement for the treatment of severe aortic valve stenosis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content